NanOlogy
  • Home
  • About
  • Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
    • Partnering Opportunities
  • News & Publications
    • Recent News Highlights
    • Press Release Archives
    • NanOlogy In the News
    • Presentations & Publications Archive
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
Post placeholder image
May 3, 2018 in NanOlogy in the News

Boston Business Journal: NanOlogy Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac for Treatment of Prostate Cancer

NanOlogy 0 Like Post Comments Off on Boston Business Journal: NanOlogy Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac for Treatment of Prostate Cancer
Read More
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal